drugset
drugset / Trial / NCT05469126

A Drug Interaction Study of Clarithromycin and LY3502970 in Healthy Participants

NCT05469126 ↗

Phase 1 Completed 26 enrolled Eli Lilly and Company
Non-randomizedSequentialOpen-labelBasic science

Summary

The main purpose of this study is to determine the levels of study drug called LY3502970 in the blood stream when administered alone and in combination with clarithromycin in healthy participants. This study will last up to approximately 85 days for each participant.

Timeline

Start
2022-08-01
Primary completion
2022-11-03
Completion
2022-11-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Clarithromycin Small molecule 500 mg Oral
Subject Orforglipron Small molecule 3 mg Oral

Indications

No indication recorded.